Orthofix (NSDQ:OFIX) said interim CFO Emily Buxton will take the reins as its permanent CFO. Buxton has been interim CFO since October 2012, following stints as controller and CFO of the orthopedic device maker’s global orthopedics operation.
Orthofix also recently appointed a new president and CEO, Brad Mason, following the resignation of longtime chief Robert Vaters.
"I am delighted to announce the appointment of Emily to this critical position, particularly at this time in Orthofix’s history when we are so well positioned for the future. It will be my pleasure to work side by side with her and the rest of the executive team as we explore the many opportunities we have to define the Orthofix of tomorrow," Mason said in prepared remarks.
Independent director Robert Kill will serve as interim CEO while Uroplasty’s board conducts a search to fill the position permanently.
Oncologix Tech CEO retires
Oncologix Tech CEO Anthony Silverman retired last month, leading the Grand Rapids, Mich.-based company to hire Barry Griffith as chief executive, president and chairman.
New CEO for Exalenz Bioscience
Exalenz Bioscience appointed Larry Cohen as its new CEO. The Modin, Israel-based medical diagnostic developer said the appointment of an American CEO is aimed at extending its U.S. operations. The company thanked ex-CEO Steven Eitan for overseeing its growth from a pre-business stage to global commercialization.
Cohen was CEO of diagnostics maker Hemosense and the VP of marketing & sales at Beckman Instruments, Fisher Medical Group and Ortho Clinical Diagnostics.